top of page

Product Pipeline

Our cutting edge anti-bacteria and anti-infective products are quickly progressing through target identification, lead selection and optimization, nonclinical and clinical testing phases.

All of our anti-infective programs are funded by the National Institutes of Health via the SBIR grants. It is of utmost importance to AimMax Therapeutics to protect the objectivity and integrity of its research and development activities to ensure public trust and to meet scientific and ethical standards of the NIH-funded research. To view AimMax Therapeutics Financial Conflict of Interest (FCOI) Policy, please click here.

Product Pipeline: Text
bottom of page